The Zhitong Finance App learned that Kangsheng Global (09960) actively explores science and technology related to precision medicine and clinical application research, and strives to make original contributions to basic scientific issues and translational research on major diseases in biomedicine. This year, Kangsheng Global continued to cultivate in the field of academic research and made significant progress in various research directions.

Kangsheng Global 2024 Academic Achievements

Participating in the project, more than 70 articles were published, with a cumulative impact factor of more than 300 points. Among them, Kangsheng Global signed 18 articles, a cumulative impact factor of 101.1, and published 10 articles in one work/newsletter, with a total impact factor of 46.9.

It participated in applying for projects at the national, provincial and municipal levels, and successfully approved 8 projects, with a total approval amount of 14.4 million yuan. Among them, the “Major Project for the Transformation of Achievements in Wuhan” led by Professor Huang Shiang, Chairman of Kangsheng Global Group, was approved for 6.5 million yuan.

Presentation of the results of some projects

1. Apoptosis (IF=6.1) | Dual Disease Combined with Machine Learning Reveals Potential Copper Death Mechanisms in COVID-19 DLBCL Infection for the First Time

Copper poisoning-related genes (CRGs) have been shown to be potential therapeutic targets for cancer; however, the molecular mechanism of CRGs in DLBCL infection with COVID-19 has not been reported. The study revealed for the first time the mechanism of copper death in DLBCL infected with COVID-19 through transcriptomics, machine learning, and cellular function experiments, and clarified the potential role of the copper death-related gene DLD in the pathogenesis of DLBCL-infected COVID-19 patients. Li Yun of Kangsheng Global Research Project Team undertook data analysis work and published articles as co-corresponding author.

2. J Cell Mol Med (IF=4.3) | Single gene pan-cancer analysis reveals potential prognostic and pathologic mechanisms of UBA1 in DLBCL and AML

UBA1 plays an important role in immune regulation and cellular function. However, the functional mechanism and role of UBA1 in pan-cancer have not been fully elucidated, and its value in hematologic tumors such as DLBCL and AML has not been explored. The study revealed the potential mechanism of UBA1 in hematologic tumors (DLBCL and AML) for the first time through transcriptomics, machine learning, and cellular function experiments. Li Yun of Kangsheng Global Research Project Team undertook data analysis work and published articles as co-corresponding author.

3. Nat Commun (IF=14.7) | Specific Pharmacology and GI/O Protein Responses to Certain Natural G Protein-Coupled Receptors (GPCRs) in Neurons

G protein-coupled receptors (GPCRs) are the largest family of membrane proteins and are important drug targets. The discovery of drugs targeting these receptors and their G protein signaling characteristics is mainly based on tests of modified receptors expressed in allogeneic cells. However, GPCR responses may vary in their native environment. The findings show the importance of using biosensors compatible with primary cells to assess the activity of endogenous GPCRs in their natural environment. Kangsheng Global's Zhou Yiwei undertook data analysis work and published an article as co-first author.

4. Cell (IF=66.8) | Retrovirus-based total RNA-mediated gene-writing (gene-writing) technology

An all-RNA-mediated target gene integration method can reduce immunogenicity, achieve effective delivery through non-viral vectors, and reduce the risk of random mutations. In this context, the naturally occurring R2 reverse transcription transposon is promising due to its site-specific integration characteristics. The study successfully pioneered a revolutionary gene-editing technology — a whole-RNA-mediated gene-writing (gene-writing) technology based on retroviruses. This breakthrough has enabled accurate targeted gene integration in human cells and brought unprecedented progress to the field of genomics engineering. The research results were published in the journal “Cell” on July 8, 2024. Kangsheng Global participated in sequencing and data analysis work.

5. Leukemia (IF=12.8) | Genetic and Transcriptomic Analysis of Diffuse Large B-Cell Lymphoma Patients Diagnosed with Poor Prognosis Within 2 Years

Despite improvements in clinical outcomes of DLBCL, a large percentage of patients still face refractory/recurrence (R/R) challenges after receiving first-line R-CHOP treatment. The study combined clinical, genetic, and transcriptome data from 2,805 patients treated with R-CHOP in seven independent cohorts. 24 gene expression scores were developed and validated as independent prognostic predictors of treatment outcomes. When integrated with existing genetic or cell-derived subtypes, the score also demonstrated efficacy for further stratification in high-risk patients. Also, based on these findings, an online analysis tool () was developed that can be used to predict the prognosis of DLBCL patients. Kangsheng Global's Ye Xiaofei participated in the data analysis work.

Kangsheng Global is equipped with a large-scale multi-omics one-stop research service platform covering the whole country. It can provide one-stop multi-omics research services such as genomics, transcriptome, epigenome, microbiome, single cell, spatiotemporal group, proteome, metabolome, etc., to help application and promotion in life science, precision medicine, and pharmaceutical development.